Showing results (301-310 of 390) with videos related to

Sort By:
Pageof 39
International Journal of MS Care|March 1, 2017
A Framework of Care in Multiple Sclerosis, Part 2: Symptomatic Care and BeyondScott D Newsome, Philip J Aliotta, Jacquelyn Bainbridge, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 21, 2025
DISCOntinuation of disease-modifying therapies in MS: The DISCOMS extension trialJohn R Corboy, Robert J Fox, Gary Cutter, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 16, 2018
Predictive validity of NEDA in the 16- and 21-year follow-up from the pivotal trial of interferon beta-1bDouglas S Goodin, Anthony T Reder, Anthony L Traboulsee, et al.
Annals of Internal Medicine|February 1, 2003
Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammographyPatricia A Carney, Diana L Miglioretti, Bonnie C Yankaskas, et al.
Epilepsy & Behavior : E&B|August 14, 2018
Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective studyJerzy P Szaflarski, Elizabeth Martina Bebin, Gary Cutter, et al.
Multiple Sclerosis and Related Disorders|March 17, 2023
Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosisLana Zhovtis Ryerson, John F Foley, Gilles Defer, et al.
Therapeutic Advances in Neurological Disorders|September 24, 2024
Maintenance of zilucoplan efficacy in patients with generalised myasthenia gravis up to 24 weeks: a model-informed analysisGuillemette de la Borderie, Damien Chimits, Babak Boroojerdi, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 21, 2025
Feasibility of Simon Two-Stage Futility Trials in People with Early, Symptomatically Treated Parkinson's DiseaseMarcus W Koch, Lorraine V Kalia, Justyna Sarna, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 20, 2024
Statistical considerations when estimating time-saving treatment effects in Alzheimer's disease clinical trialsGuoqiao Wang, Gary Cutter, Neil P Oxtoby, et al.
Multiple Sclerosis and Related Disorders|October 2, 2023
Magnetic resonance fingerprinting in multiple sclerosisDaniel Ontaneda, Vikas Gulani, Anagha Deshmane, et al.
Pageof 39